H2 KOSPI vs KOSDAQ: Who Will Win? Stocks to Buy Immediately When Interest Rate Burden Decreases

H2 KOSPI vs KOSDAQ: Who Will Win? Stocks to Buy Immediately When Interest Rate Burden Decreases | Lee Jaegyu, SK Securities PB Deputy Manager [Focus Today's Stocks]
Watch on YouTube ↗  |  August 10, 2026 at 11:30  |  43:03  |  3PRO TV (삼프로TV)
Speakers
Lee Jae-kyu — PB Deputy Manager, SK Securities

Summary

Lee Jaegyu of SK Securities argues that the Korean market will continue its uptrend, but the second half will see KOSDAQ outperform KOSPI as the market broadens. He recommends shifting some weight from an overheated semiconductor concentration in Samsung Electronics and SK hynix into KOSDAQ, oversold KOSPI large caps like Hanwha Aerospace and shipbuilders, and Korean biotech large caps such as Samsung Biologics, Celltrion, and Alteogen. He also highlights Samsung Electro-Mechanics as a better near-term semiconductor play. Macro stability, lower rate hike odds, and passive flows support the rotation.

  • KOSDAQ set to outperform KOSPI in H2 due to smaller market cap and oversold sectors catching up.
  • KOSPI uptrend intact on stable macro environment, but slower than KOSDAQ.
  • Concentration in Samsung Electronics and SK hynix should be reduced; other sectors will lead.
  • Samsung Electro-Mechanics preferred over Samsung Electronics/SK hynix for new entries on chart and MLCC demand.
  • Korean biotech large caps (Samsung Biologics, Celltrion, Alteogen) attractive as US biotech indices near highs and rate hike fears ease.
  • Oversold quality KOSPI names like Hanwha Aerospace, HD Hyundai Heavy, Hanwha Engine poised to rebound.
  • Macro drivers: stable USD/KRW, oil, declining U.S. rate hike probability, passive ETF inflows into KOSDAQ.
Ideas
Lee Jae-kyu PB Deputy Manager, SK Securities 0:03
Maintain KOSPI, uptrend on stability
KOSPI will also continue its uptrend because macro factors are stable, no major crisis is present, and the index is technically holding above its recent low, suggesting support. However, the upside may be slower compared to KOSDAQ.
Lee Jae-kyu PB Deputy Manager, SK Securities 2:15
Overweight KOSDAQ for H2 outperformance
KOSDAQ will outperform KOSPI in the second half of the year. The KOSDAQ market capitalization is only about 400 trillion won versus KOSPI's 5,000 trillion won, so relatively small inflows can generate larger moves. Overly concentrated KOSPI positioning (especially in Samsung Electronics and SK hynix) needs to be rebalanced, and macro conditions such as stabilizing USD/KRW, oil, and declining rate hike expectations are favorable for risk assets. The market is returning to a broader pattern where previously oversold sectors and mid/small caps catch up.
Lee Jae-kyu PB Deputy Manager, SK Securities 11:23
Reduce Samsung Electronics, SK hynix concentration
Samsung Electronics and SK hynix dominated the first half, but the second half will likely see a more balanced market. Being overwhelmingly concentrated in these two stocks risks underperformance as other sectors recover. Investors should reduce weight and diversify into other areas, even though the stocks are cheap.
Lee Jae-kyu PB Deputy Manager, SK Securities 26:14
Oversold quality large caps to rebound
Oversold large-cap KOSPI stocks with solid earnings, such as defense and shipbuilding names, will rebound in H2 as market rotation broadens away from first-half semiconductor dominance. Hanwha Aerospace, HD Hyundai Heavy Industries, and Hanwha Engine are specifically named.
Lee Jae-kyu PB Deputy Manager, SK Securities 36:55
Samsung Electro-Mechanics favored for near-term entry
Samsung Electro-Mechanics is now a better near-term entry than Samsung Electronics or SK hynix. The stock is holding above its 120-day moving average, and there is a positive divergence between rising EPS and a falling stock price. High-value MLCC demand is growing and general MLCC supply is tightening, supporting the outlook.
Lee Jae-kyu PB Deputy Manager, SK Securities 39:11
Korean biotech large caps set to rally
Korean biotech large caps are attractive as the US biotech indices (NBI, XBI) have rebounded near highs and the probability of further rate hikes has declined markedly, reducing pressure on growth sectors. These names were heavily oversold in H1 and can benefit from rotation back into the sector.
Up Next

This 3PRO TV (삼프로TV) video, published August 10, 2026, features Lee Jae-kyu discussing EWY, KOSDAQ Index, KOSDAQ 150 ETF, 005930.KS, 000660.KS, 012450.KS, 329180.KS, 042660.KS, 009150.KS, 207940.KS, 068270.KS, 196170.KQ. 6 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Lee Jae-kyu  · Tickers: EWY, KOSDAQ Index, KOSDAQ 150 ETF, 005930.KS, 000660.KS, 012450.KS, 329180.KS, 042660.KS, 009150.KS, 207940.KS, 068270.KS, 196170.KQ